Supply Chain Ecosystem Analysis now part of DBMR Reports
Asia-Pacific Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies and NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Bispecific Antibodies), Application (Cancer, Immunoproliferative Disorders, Acute Infectious Diseases, Gastrointestinal Diseases, and Others), End User (Research & Academic Institutes, Hospitals, and Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, and Others)-Industry Trends and Forecast to 2030.
The Asia-Pacific natural killer (NK) cell therapeutics market comprises features such as the increasing need for better therapeutics options that will impact the launching of a new product by manufacturers into the market enhancing its demand as well as increasing investment in R&D leading to the market growth. Currently, various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative NK cell therapies, which is expected to provide various other opportunities for market growth. However, the lack of specificity and poor in-vivo survival of the cells, and the high cost associated with therapies are expected to restrain market growth in the forecast period.
The Asia-Pacific natural killer (NK) cell therapeutics market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyzes that Asia-Pacific natural killer (NK) cell therapeutics market will grow at a CAGR of 45.2% during the forecast period of 2023 to 2030.
The Asia-Pacific natural killer (NK) cell therapeutics market report provides details of market share, new developments, product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief, our team will help you create a revenue-impact solution to achieve your desired goal.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in Million and Pricing in USD
|
|
Segments Covered
|
Therapeutics (NK Cell Therapies and NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Bispecific Antibodies), Application (Cancer, Immunoproliferative Disorders, Acute Infectious Diseases, Gastrointestinal Diseases, and Others), End User (Research & Academic Institutes, Hospitals, and Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, and Others)
|
|
Countries Covered
|
Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific
|
|
Market Players Covered
|
Merck KGaA, Bristol-Myers Squibb Company, Glycostem, Sanofi, Cytovia Therapeutics, ImmunityBio, Inc., Biohaven Pharmaceuticals, Fate Therapeutics, EMERcell, Phio Pharmaceuticals, PersonGen BioTherapeutics, Innate Pharma, Inc., INmuneBIO, Gamida Cell, Acepodia Inc., Affimed GmbH, Multimmune GmbH, iCell Gene Therapeutics, Takeda Pharmaceutical Company Limited, and Regeneron Pharmaceuticals Inc. among others
|
Market Definition
Natural killer (NK) cells are large granular lymphocytes that have the ability to quickly respond to a pathological challenge. They are important components of the innate immune system and play an important role in generating an immune response against malignancies and infectious diseases caused by viral pathogens. They have been recognized to induce the direct killing of targeted cells involving cancer cells. They have the ability to recognize the multitude of infected cells without being dependent on a single antigen-expressing cell.
NK cells secrete cytokines and chemokines that recruit other immune cells such as T cells and B cells, which enhances the immune response against the tumor cells. As NK cells do not express T cell receptors, they induce a low risk of graft-versus-host disease. Moreover, iPSC cell lines derived NK cell therapy that is CAR-NK therapy overcomes the need for a long and complex manufacturing process that allows patients with aggressive tumors to afford tumor treatment as soon as possible. Along with this iPSC derived NK cells can be infused repeatedly, which enhances the immune response with dose regulation.
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
DRIVERS
Chronic diseases are diseases that generally occur in older adults that can be controlled but not cured such as heart disease, arthritis, diabetes, stroke, or cancer. They are a worldwide healthcare problem concern. The change in lifestyle along with physical inactivity, unhealthy diet, and tobacco use is increasing the burden of chronic diseases all over the world.
An increasing number of patients population with chronic diseases led the scientist and researchers to work on a new innovative therapeutic approach so as to provide patients with the best curative treatment option, which can be achieved by using NK cell therapy that has the potential to generate a strong immune response and has the anti-tumor capability as well.
As cancer is a devastating disease and available treatment options may cause the reoccurrence of tumors, the need for the best therapeutic approach is increasing day by day. Immunotherapies have attracted a lot of attention in recent years for the treatment of various types of malignancies. Among the immunotherapies, CAR–T cell therapies have been studied and were used as well but have several limitations, which led to the development of NK cell therapies. As a drug based on an NK cell therapeutic approach has not been approved yet, it thus needs to raise awareness among the population.
This is why several organizations and market players are launching a campaign to enhance awareness regarding NK cell therapies.
OPPORTUNITY
Various strategic initiatives are adopted by market players which involve expansion, acquisition, and collaboration among others. These initiatives help them to increase the company’s product portfolio leading to market expansion and hence enhancing the product demand among customers, which ultimately leads the players to earn maximum revenue.
As the demand for effective and affordable NK cell immunotherapy is increasing worldwide, these strategic initiatives are taken by top market players aimed at enhancing business operations and earning more profitability in the market.
RESTRAINT/CHALLENGE
Lack of specificity and poor in-vivo survival of NK cells poses a challenge in front of manufacturers dealing in the market. The lack of specificity of NK cells leads to targeting the wrong cells, which can lead to ineffective treatment. Along with this, the lack of specificity and poor in-vivo survival of NK cells also reduces the therapeutic effect of administered NK cell therapy.
Such problems decrease the credibility of therapy used in clinical trials and pose a challenge in front of manufacturers while getting approval.
Recent Developments
The Asia-Pacific natural killer (NK) cell therapeutics market is segmented into five notable segments based on therapeutics, approaches, application, end-user, and distribution channel. The growth among these segments will help you analyze niche pockets of growth and strategies to approach the market and determine the core application areas and the difference in the target markets.
Therapeutics
Based on therapeutics, the market is segmented into NK cell therapies and NK cell directed antibodies.
Approaches
Based on approaches, the market is segmented into antibody-dependent cell-mediated cytotoxicity (ADCC) and bispecific antibodies.
Application
Based on application, the market is segmented into cancer, immunoproliferative disorders, acute infectious diseases, gastrointestinal diseases, and others.
End User
Based on end user, the market is segmented into hospitals, specialty clinics, and research & academic institutes.
Distribution Channel
Based on distribution channel, the market is segmented into hospital pharmacies, direct tender, and others.
The Asia-Pacific natural killer (NK) cell therapeutics market is categorized into five notable segments: therapeutics, approaches, application, end-user, and distribution channel.
The countries covered in this market report are China, Japan, India, South Korea, Singapore, Thailand, Malaysia, Australia, Philippines, Indonesia, and the rest of Asia-Pacific.
Japan dominates the Asia-Pacific region due to rising awareness of regular health check-ups.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.
The Asia-Pacific natural killer (NK) cell therapeutics market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the Asia-Pacific natural killer (NK) cell therapeutics market are, Merck KGaA,, Bristol-Myers Squibb Company, Glycostem, Sanofi, EMERcell, Phio Pharmaceuticals, Affimed GmbH, Multimmune GmbH, and Takeda Pharmaceutical Company Limited.
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.